Edition:
United Kingdom

Novo Nordisk A/S (NOVOb.CO)

NOVOb.CO on Copenhagen Stock Exchange

275.50DKK
3:49pm BST
Change (% chg)

kr.-4.50 (-1.61%)
Prev Close
kr.280.00
Open
kr.275.00
Day's High
kr.278.40
Day's Low
kr.273.50
Volume
1,531,946
Avg. Vol
2,322,548
52-wk High
kr.354.80
52-wk Low
kr.265.15

Chart for

About

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity... (more)

Overall

Beta: 1.53
Market Cap(Mil.): kr.532,553.38
Shares Outstanding(Mil.): 1,912.56
Dividend: 3.00
Yield (%): 2.82

Financials

  NOVOb.CO Industry Sector
P/E (TTM): 17.44 29.75 32.14
EPS (TTM): 15.97 -- --
ROI: 72.39 13.18 12.83
ROE: 80.23 15.14 14.95

Factbox: Potential candidates to become Danske Bank's next CEO

COPENHAGEN Denmark's largest lender Danske Bank is looking for a new chief executive in the wake of a money laundering scandal centered on $235 billion in transactions that passed through its Estonia branch.

17 Oct 2018

Deals of the day-Mergers and acquisitions

Oct 15 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday:

15 Oct 2018

Novo Nordisk hires AstraZeneca executive to revive struggling biopharma unit

COPENHAGEN Novo Nordisk is in advanced talks to acquire assets to bolster its struggling biopharma business, its chief executive said on Monday after the drugmaker announced it had hired an AstraZeneca executive to head the unit.

15 Oct 2018

UPDATE 1-Novo Nordisk hires AstraZeneca executive to revive struggling biopharma unit

COPENHAGEN, Oct 15 Novo Nordisk is in advanced talks to acquire assets to bolster its struggling biopharma business, its chief executive said on Monday after the drugmaker announced it had hired an AstraZeneca executive to head the unit.

15 Oct 2018

Novo Nordisk could close biopharma acquisition this year -CEO

COPENHAGEN, Oct 15 Novo Nordisk might be able to complete an acquisition within its struggling biopharma business this year, its chief executive told Reuters on Monday.

15 Oct 2018

Novo Nordisk picks AstraZeneca executive to head biopharma business

COPENHAGEN, Oct 15 Novo Nordisk has hired AstraZeneca's head of cardiovascular and metabolic diseases to head its biopharma business, which has been struggling with declining sales and a failed acquisition.

15 Oct 2018

Lilly's diabetes drug data impresses, hurts rival Novo's shares

Eli Lilly and Co said on Thursday its new two-in-one diabetes drug was successful in lowering blood sugar and reducing weight, sending its shares to a record high and weighing on those of arch-rival Novo Nordisk .

04 Oct 2018

UPDATE 2-Lilly's diabetes drug data impresses, hurts rival Novo's shares

Oct 4 Eli Lilly and Co said on Thursday its new two-in-one diabetes drug was successful in lowering blood sugar and reducing weight, sending its shares to a record high and weighing on those of arch-rival Novo Nordisk .

04 Oct 2018

BRIEF-Novo Nordisk Plans First Global Launch Of Connected Insulin Pens

* NOVO NORDISK PLANS FIRST GLOBALLAUNCH OF CONNECTED INSULIN PENS AND ANNOUNCES KEY DIGITAL HEALTH PARTNERSHIPS

01 Oct 2018

Novo Nordisk to cut 250 jobs in the United States

COPENHAGEN Denmark's Novo Nordisk will cut around 250 jobs in the United States, a spokesman told Reuters on Friday, adding the drugmaker would also hire an as-yet undetermined number of staff to new positions.

28 Sep 2018

Earnings vs. Estimates